In this small cohort of enriched liquid biopsies, it was evident that BRCAm ovarian cancer patients undergoing chemotherapy had more positive γ-H2AX cells (mean 12.3/100 cells) compared with BRCA wt patients (mean 1.7/100 cells; Figure 6). The gene discussed is H2AX; the disease is ovarian carcinoma.